Premium
Pharmacokinetics and Antitumor Effects of an Interleukin‐2 lmmunocomplexing Agent in Murine Renal Cell Carcinoma
Author(s) -
Oya Mototsugu,
Marumo Ken,
Murai Masaru,
Tazaki Hiroshi
Publication year - 1996
Publication title -
international journal of urology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.172
H-Index - 67
eISSN - 1442-2042
pISSN - 0919-8172
DOI - 10.1111/j.1442-2042.1996.tb00499.x
Subject(s) - medicine , pharmacokinetics , renal cell carcinoma , immune system , monoclonal antibody , in vivo , pharmacology , interleukin 2 , cancer research , interleukin , antibody , pathology , cytokine , immunology , biology , microbiology and biotechnology
Background: Conventional therapy for renal cell carcinoma (RCC) using systemic administration of interleukin‐2 (IL‐2) has shown limited anti‐tumor action. The purpose of this study was to investigate the anti‐tumor effects of a newly developed immune complex of IL‐2 (IC) against RCC. Methods: IC was prepared by mixing IL‐2 and an anti‐IL‐2 monoclonal antibody at a molar ratio of 2:l. The pharmacokinetics and anti‐tumor effects of IC were then studied in a murine KCC line, Renca. Results: Serum IL‐2 levels were sustained longer in mice given IC than in mice given IL‐2 alone after either subcutaneous or intratumoral injections. After an intratumoral injection of IC, the IL‐2 concentration in the tumor nodules remained higher compared with mice given IL‐2 alone. The anti‐tumor effect was most pronounced in mice treated with intratumoral injections of 1C. Conclusions: Results obtained here indicate that an immune complex of IL‐2 provides d useful tool for the treatment of RCC by altering the pharmacokinetics of IL‐2 in vivo.